• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21045 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of robotic-assisted orthopedic surgery for knee and hip arthroplasty]
2024     Norwegian Institute of Public Health (NIPH) [Robot-assisted prostatectomy for prostate cancer]
2024     Norwegian Institute of Public Health (NIPH) [Robot-assisted rectal resection for rectal cancer]
2024     Norwegian Institute of Public Health (NIPH) [Robotic hysterectomy]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of phalloplasty as a masculinizing genital surgery: a systematic review]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Liquid biopsy utility in the colorectal cancer's management stages I-IV]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety of non-reabsorbable clips in living donor laparoscopic nephrectomy]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: Cervical cancer: transition from from Pap test screening to HPV testing]
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of adult patients with chronic immune thrombocytopenia after failure of first-line therapies
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Dental bridges for partial tooth loss
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Optune - for the treatment of adult patients with newly diagnosed glioblastoma]
2023     WorkSafeBC Cold plunges as treatment for concussions
2023     WorkSafeBC Flotation therapy as treatment for concussions
2023     WorkSafeBC Efficacy of under-mask beard covers in quantitative fit testing of tight-fitting disposable respirators
2023     WorkSafeBC Causal association between COVID-19 infection and irritable larynx syndrome
2023     WorkSafeBC Migraines and the (Moderna) COVID-19 vaccine
2023     WorkSafeBC Botulinum toxin as treatment for neck strains
2023     WorkSafeBC Esketamine as treatment for depression and PTSD
2023     WorkSafeBC Platelet rich plasma in treating (recurrent) anterior shoulder dislocation
2023     WorkSafeBC Causal association between carpal tunnel release surgery and trigger finger
2023     WorkSafeBC Causal association between SARS-Cov-2 infection and the development of trigeminal neuralgia
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: models for coordinating interhospital transfers in critical care]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: asthma management in children and adults]
2023     Health Technology Wales (HTW) Control contact lenses and spectacles for the treatment of myopia in children
2023     Health Information and Quality Authority (HIQA) Methods for generic justification of new practices in ionising radiation
2023     Health Information and Quality Authority (HIQA) Analysis of public consultation surveys to inform the work of the Public Health Reform Expert Advisory Group [protocols and report]
2023     Health Information and Quality Authority (HIQA) Rapid health technology assessment of the extension of the seasonal influenza vaccination programme to include those aged 50 to 64 years (general population)
2023     NIHR Health Technology Assessment programme Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: implantable medical device tracking methods]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Economic dimensions of community nursing: A systematic literature review]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence search for the S3 guideline on advice for vitamin D substitution]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for gallbladder removal]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene (ß-thalassaemia in patients ≥ 12 years); assessment according to §35a Social Code Book V; search for disease registries]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) – Second Addendum to Commission A23-03]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Setmelanotide (Bardet Biedl syndrome) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etranacogene dezaparvovec (haemophilia B) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tabelecleucel (relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), pretreated, 2 years and older) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene autotemcel (transfusion-dependent β-thalassaemia) - Assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belantamab mafodotin (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (heart failure with LVEF > 40 %) – Addendum to Commission A23-11]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 3 and 4) – Addendum to Commission A23-15]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 1 and 2) – Addendum to Commission A23-14]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (previously untreated chronic lymphocytic leukaemia) – Addendum to Commission A23-04]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotorasib (NSCLC) – Addendum to Commission A23-06]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer) – Addendum to Commission A23-07]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) – Addendum to Commission A23-03]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lutetium vipivotide tetraxetan (prostate cancer) – Addendum to Commission A23-01]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Loncastuximab tesirine (DLBCL and HGBL) - Benefit assessment according to § 35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (myelodysplastic syndrome) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (transfusion-dependent beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (chronic lymphocytic leukaemia) – Addendum to Commission A22-130]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (Crohn disease) – Addendum to Commission A22-133]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Latanoprost/netarsudil (primary open-angle glaucoma and ocular hypertension) – Addendum to Commission A22-129]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (Crohn disease) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lasmiditan (migraine) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Deucravacitinib (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for brexucabtagene autoleucel: Review of the study protocol (Version 2.0) and statistical analysis plan (Version 2.0) – Third Addendum to Commission A21-130]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (ovarian cancer) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dulaglutide (type 2 diabetes in children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (malignant biliary cystic tumour [BCT]) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis, 6 months to 5 years) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (prurigo nodularis) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (eosinophilic oesophagitis) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darolutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (treatment-resistant major depressive disorder) – Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection for brexucabtagene autoleucel acc. to the Law for More Safety in the Supply of Medicines (GSAV)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: use of healthcare services by people with confirmed SARS-CoV-2 infection and those with no documented evidence of infection]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: pediatric cancer predisposition using next-generation sequencing panels]
2023     Austrian Institute for Health Technology Assessment (AIHTA) Robot-assisted surgery in thoracic and visceral indications – Update 2023
2023     Norwegian Institute of Public Health (NIPH) [Brace compression for treatment of pectus carinatum: a rapid health technology assessment]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Invasive electroencephalography for drug-resistant epilepsy]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Transbronchial biopsy guided by endobronchial ultrasound (EBUS) in pathologies accesible by transbronchial puncture that required anatomopathological diagnosis]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Dielectric radiofrequency for the treatment of primary hyperhidrosis and bromhidrosis]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Triple-phase computed tomography in patients with liver lesion]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Polymeric diet rich in TGF-β for inflammatory bowel disease in pediatric patients]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Combination diagnostic tests offered as part of preventive health checks exams in overall population]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Sapropterin in patients with phenylketonuria]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Holmium laser in non-prostate endourologic conditions]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Lipogems® System for autologous adipose tissue-derived mesenchymal stem cells transfer in orthopedic conditions]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Mobile cardiopulmonary exercise test in athletes or cardiopulmonary rehabilitation]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Lecanemab in Alzheimer’s Disease]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Angioplasty and stenting in patients with carotid artery stenosis]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Non-invasive monitoring of intracranial compliance and intracranial pressure in central nervous system lesions]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in psychiatry]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in respirology]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in pediatrics]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in neurology]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in internal medicine]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in hematology/oncology]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in general surgery]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: optical genome mapping - diagnosis and prognostic stratification of hematological malignancies]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual genes panels of pediatric cancers by NGS of somatic exome and transcriptome - evaluation report of an analysis developed by the RQDM]
2023     Health Information and Quality Authority (HIQA) Expansion of the childhood immunisation schedule to include varicella (chickenpox) vaccination: health technology assessment
2023     Health Information and Quality Authority (HIQA) Interventions to improve long COVID symptoms: a systematic review